Biotechnology
Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule Excerpt from the Press Release: SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters…
Read More
Long COVID Trial Topline data expected in early Q3 2022 NASH Trial interim data expected in late Q3 2022 OHE Trial Suspended Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that…
Read More
Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027, an inhibitor of TGFβ signaling Excerpt from the Press Release: SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) — Yingli Pharma US, Inc, (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs for cancers and other diseases with…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,”…
Read More
Excerpt from the Press Release: PITTSBURGH and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the presentation of preclinical pharmacokinetics (PK) and…
Read More
Pre-IND meeting request granted by FDA’s Division of Neurology I Excerpt from the Press Release: BOSTON, May 12, 2022 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that the US Food and Drug Administration (FDA) Office of Orphan…
Read More
PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway Plans underway for…
Read More
Excerpt from the Press Release: CARLSBAD, Calif., April 25, 2022 /PRNewswire/ — DCN Dx, a global leader in the end-to-end development, manufacture, and commercialization of point-of-use tests, today announced it has completed its acquisition of Biomed Diagnostics, Inc., a microbiological testing products company based in White City, Oregon. The acquisition expands DCN Dx’s footprint in the point-of-use testing…
Read More
Excerpt from the Press Release: HOPEWELL, N.J. & CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a 501(c)(3) organization committed to transforming the cancer experience for patients and their families…
Read More
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with navicixizumab-paclitaxel combination in heavily pretreated platinum-resistant ovarian cancer patients Xerna™ TME Panel shows enhanced response in biomarker positive (62%) vs. biomarker negative patients (25%) Results support co-development of navicixizumab and Xerna TME Panel in ovarian cancer Excerpt from the…
Read More